08:00 Tue 17 Jul 2018
OptiBiotix Health - Grant of Options
Grant of Options
Director |
Number of options |
Exercise price |
|
385,000 |
73p |
Sofia Kolyda |
165,000 |
73p |
Others |
165,000 |
73p |
Under the rules of the Scheme the participants have up to 30 days from the date of offer,
The options have performance criteria attached to them which includes a doubling in the share price and significant revenue targets. Option holders can only purchase and/or sell shares once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.
A further announcement will be made confirming the Effective Date.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was
Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to attract and retain key staff who deliver to performance targets which build shareholder value is important to OptiBiotix' continued success. The granting of share options helps OptiBiotix compete with the remuneration packages offered by larger corporates and incentivises the team to focus both effort and activity on rapidly growing revenues and building shareholder value. These options are offered to staff do not become exercisable (i.e. sellable) until they achieve significant performance targets which if achieved will create substantive shareholder value".
For further information, please contact:
|
|||
|
Contact via Walbrook below |
||
|
|
||
|
Tel: 020 7213 0880 |
||
|
|
||
|
|
||
finnCap (Broker) |
Tel: 020 7220 0500 |
||
|
|
||
|
|
||
|
|
||
|
Tel: 020 7933 8780 or optibiotix@walbrookpr.com |
||
|
Mob: 07876 741 001 |
||
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE